2024
Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James L, Klaassen F, Sweeney S, Furin J, Franke M, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies N. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. PLOS Medicine 2024, 21: e1004401. PMID: 38701084, PMCID: PMC11101189, DOI: 10.1371/journal.pmed.1004401.Peer-Reviewed Original ResearchQuality-adjusted life yearsStandard of careDrug susceptibility testingRifampicin-resistant tuberculosisRR-TBEnd-of-treatmentLonger regimensTreatment strategiesTreatment outcomesBurden of drug-resistant TBCost-effective treatment strategyResistance to amikacinDrug-resistant TBSevere adverse eventsHistory of TBResistance to delamanidTB drug resistanceAnti-TB drugsLifetime costsAssociated treatment outcomesFQ-R.Average timeNatural history of TBFluoroquinolone resistanceFQ-R
2017
Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies
Wiesch P, Clarelli F, Cohen T. Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies. PLOS Computational Biology 2017, 13: e1005321. PMID: 28060813, PMCID: PMC5257006, DOI: 10.1371/journal.pcbi.1005321.Peer-Reviewed Original ResearchConceptsOptimal dosingTreatment strategiesOnset of actionAntibiotic treatment strategiesAntibiotic concentrationsOptimal therapyFrequent dosingHigh dosesBacterial infectionsDrug concentrationsDosingBacterial replicationAntibioticsPhysiological fluctuationsAntibiotic effectCellsHIVBacterial growthTherapyCancerInfectionMalariaDoses
2015
Classic reaction kinetics can explain complex patterns of antibiotic action
Abel Zur Wiesch P, Abel S, Gkotzis S, Ocampo P, Engelstädter J, Hinkley T, Magnus C, Waldor MK, Udekwu K, Cohen T. Classic reaction kinetics can explain complex patterns of antibiotic action. Science Translational Medicine 2015, 7: 287ra73. PMID: 25972005, PMCID: PMC4554720, DOI: 10.1126/scitranslmed.aaa8760.Peer-Reviewed Original ResearchConceptsOptimal dosing strategiesAntibiotic treatment strategiesTime-kill curvesAntibiotic effectGrowth suppressionCell formationChemotherapeutic regimensClinical trialsDosing strategiesTreatment strategiesTuberculosis therapyPersister cell formationDrug effectsBacterial infectionsVariety of antibioticsHow competition governs whether moderate or aggressive treatment minimizes antibiotic resistance
Colijn C, Cohen T. How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance. ELife 2015, 4: e10559. PMID: 26393685, PMCID: PMC4641510, DOI: 10.7554/elife.10559.Peer-Reviewed Original Research
2014
The path of least resistance: aggressive or moderate treatment?
Kouyos RD, Metcalf CJ, Birger R, Klein EY, Wiesch P, Ankomah P, Arinaminpathy N, Bogich TL, Bonhoeffer S, Brower C, Chi-Johnston G, Cohen T, Day T, Greenhouse B, Huijben S, Metlay J, Mideo N, Pollitt LC, Read AF, Smith DL, Standley C, Wale N, Grenfell B. The path of least resistance: aggressive or moderate treatment? Proceedings Of The Royal Society B 2014, 281: 20140566. PMID: 25253451, PMCID: PMC4211439, DOI: 10.1098/rspb.2014.0566.Peer-Reviewed Original Research